Evolution and treatment.
During the admission, 67/151 (44%) patients required oxygen therapy,
during a median of 4 days (IQR 2–28). Regarding respiratory support,
15/151 (10%) required high-flow ventilation (HFV) or continuous
positive airway pressure (CPAP); 11/151 (7%) required intubation and
mechanical ventilation (MV) during a median of 5 days (IQR 2–16), and
2/151 (1%) required extracorporeal membrane oxygenation therapy.
Overall, 112/151 (74%) patients received antibiotics, mainly,
azithromycin (55/112, 49%), ceftriaxone (27/112, 24%), ampicillin
(5/112, 4%) or meropenem (6/112, 5%). Antivirals were administered to
67/151 (44%) patients; the most common were remdesivir (12/67, 18%)
and lopinavir/ritonavir (10/67, 15%). Other treatments used were
hydroxychloroquine in 52/151 (34%) patients, and immunoglobulins
(3/151, 2%) or glucocorticoids (30/151, 20%).